Compare · GPCR vs NVO
GPCR vs NVO
Side-by-side comparison of Structure Therapeutics Inc. (GPCR) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GPCR and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, GPCR is up 92.3% and NVO is down 34.2% - GPCR leads by 126.5 points.
- GPCR has been more active in the news (6 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 15 for GPCR).
- Company
- Structure Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $45.51-3.23%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- -5.53%
- +13.32%
- 1Y return
- +92.27%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 6
- 5
- Recent ratings
- 15
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GPCR
- SEC Form DEF 14A filed by Structure Therapeutics Inc.
- COO & GC Lang Matthew was granted 184,614 units of Ordinary Shares (SEC Form 4)
- SEC Form 3 filed by new insider Lang Matthew
- SEC Form 4 filed by Fmr Llc
- Structure Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
- Wolfe Research initiated coverage on Structure Therapeutics
- SEC Form 4 filed by Hall Ashley
- SEC Form 4 filed by Lin Xichen
- SEC Form 4 filed by Ma Yingli
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S